Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
- Category: Proteins and Peptides
- Published on Thursday, 29 November 2018 10:14
- Hits: 435
- TransCon CNP delivered continuous exposure of CNP at target levels for seven days with a single subcutaneous administration -
- TransCon CNP phase 1 results reinforce preclinical data and support target product profile -
COPENHAGEN, Denmark I November 28, 2018 I Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced positive preliminary results from a phase 1 trial of TransCon CNP. These results showed TransCon CNP provided continuous exposure to C-type natriuretic peptide (CNP) with a pharmacokinetic profile designed to maximize efficacy with once-weekly dosing. Additionally, the mean resting blood pressure and heart rate were unchanged from predose levels at all time points in all cohorts. Based upon these results, the company plans to initiate a phase 2 program of TransCon CNP in pediatric subjects with achondroplasia in mid-2019.
A presentation of the phase 1 results may be viewed on the Ascendis Pharma website at:
“The TransCon CNP data presented for the first time today indicate that our product candidate delivered continuous exposure of CNP at target levels over seven days, supporting once-weekly administration,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “This is an important step forward for patients. We believe that TransCon CNP is well-suited to address the challenges of people living with achondroplasia, and offers a potential new therapeutic option that looks beyond height to address the associated comorbidities. We look forward to advancing this program into clinical trials for children living with achondroplasia next year.”
In this phase 1, double-blind, randomized, placebo-controlled trial, 45 healthy adult subjects were enrolled. Five doses of TransCon CNP were tested sequentially, beginning with the lowest dose: 3.0, 10, 25, 75 and 150 microgram/kg. Up to 10 subjects in each dose cohort were randomized to receive TransCon CNP or placebo in a 4:1 ratio. After each cohort completed dosing, a Data Safety Monitoring Board (DSMB) reviewed the blinded data to approve escalation to the next higher dose. The primary endpoint was frequency of adverse events after administration of TransCon CNP. Secondary endpoints included additional safety parameters, tolerability and pharmacokinetics.
TransCon CNP is a long-acting prodrug of CNP comprised of an unmodified parent drug transiently bound to an inert carrier molecule via a proprietary linker. Following subcutaneous administration, TransCon CNP is designed to allow the body’s physiologic pH and temperature to release and activate CNP in a controlled manner over the course of one week. The carrier and linker are then cleared through the kidneys. Because the parent CNP drug is unmodified, its mode of action is expected to be maintained. TransCon CNP is in development as a treatment for achondroplasia and has potential as a treatment for other growth disorders, including fibroblast growth factor receptor (FGFR)-related skeletal disorders.
Achondroplasia is the most common form of dwarfism, affecting approximately 250,000 people worldwide. Achondroplasia results in severe skeletal complications and comorbidities, including narrowing of the foramen magnum, sleep apnea and chronic ear infections. Individuals with achondroplasia often face multiple surgeries and procedures to alleviate its many complications.
The condition is caused by an autosomal dominant activating mutation in the fibroblast growth factor receptor 3 (FGFR3) gene that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways. Preclinical and clinical data show that the CNP pathway stimulates growth. Increased CNP counteracts the effects of the FGFR3 mutation downstream, thus promoting bone growth.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technology to create new and potentially best-in-class therapies.
Ascendis Pharma currently has a pipeline of three independent rare disease endocrinology product candidates in clinical development. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology and continues to expand into additional therapeutic areas for both internal and external development.
Ascendis is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.
For more information, please visit www.ascendispharma.com.
SOURCE: Ascendis Pharma